Skip to main content
      Day 1 Recap: #ACR25 Highlights

      Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they di

      Dr. John Cush RheumNow

      4 months ago
      Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they discuss highlights and key takeaways from the Day 1 Recap on Sunday, October 26th. https://t.co/Kq8TDBLUYZ https://t.co/TNM8ZAji9w
      CAR T
      Which cells to target
      What patients & what disease
      When is right time
      In vivo (new) ex vivo
      Premeds immune sup

      Janet Pope Janetbirdope

      4 months ago
      CAR T Which cells to target What patients & what disease When is right time In vivo (new) ex vivo Premeds immune suppression What to use, ?if anything Cons Is it safe ?long term effectiveness What is failure rate ICANs and other side effects #ACRBest #ACR25 @RheumNow #26S21 https://t.co/TUSJh1hrPr https://t.co/JiqYzgBmYP
      Needle in a haystack
      What T cell to target for #autoimmune diseases

      T cell repetoires (TCR) not all are sequenced and m

      Janet Pope Janetbirdope

      4 months ago
      Needle in a haystack What T cell to target for #autoimmune diseases T cell repetoires (TCR) not all are sequenced and many can exist to present antigens Diff scales of approaches Implications CAR-T CD19 CD20 BCMA Treg HLAB27 etc! #ACR25 @ACRheum @RheumNow Alok Joglekar #26S08 https://t.co/Qgw8Akz1xk
      Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC

      TAC+GC was comparable to MMF+GC as continuous induction m

      sheila RHEUMarampa

      4 months ago
      Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN. AE rates comparable. TAC - AKI & tremor MMF - leucopenia reassuring data.more tx options. #ACR25 @RheumNow Abs2697 https://t.co/16Fd8zE5dL
      Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA?

      Pre

      David Liew drdavidliew

      4 months ago
      Toxicity is the big question about CAR-T in RA - what did the CRS/ICANS profile look like in this German ph1 in RA? Pretty good so far - but obviously will be under enormous scrutiny when we are looking at diseases with good existing therapies #ACR25 ABST0471 @RheumNow https://t.co/xXyzOwLvx8
      2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1)
      🔹All pts (n=10) met SRI-4 by wk24
      🔹DORIS remission:

      Akhil Sood MD, MS AkhilSoodMD

      4 months ago
      2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1) 🔹All pts (n=10) met SRI-4 by wk24 🔹DORIS remission: 5 (wk24), 6 (wk36–48) 🔹Residual proteinuria (n=4); renal bx (n=3) showed resolved IC deposits & inflammation 🔹CRS Grade 1 (n=6); no ICANS @RheumNow #ACR25
      LB23: Regulate-RA- ongoing Phase 1 trial of autologous CAR-Tregs in refractory RA (no lymphodepletion)
      🔹 4/6 pts had

      Akhil Sood MD, MS AkhilSoodMD

      4 months ago
      LB23: Regulate-RA- ongoing Phase 1 trial of autologous CAR-Tregs in refractory RA (no lymphodepletion) 🔹 4/6 pts had ↓ DAS28-CRP by wk 4 with rapid onset & ↓ joint counts at dose level 2 🔹 Synovial biopsies to date showed ↓ inflammatory score post-tx @RheumNow #ACR25 https://t.co/JMBbLIEmJG
      LB04: Another approach to CAR-T, CD20+/BCMA bispecific CAR-T in refractory proliferative LN:
      🔹100% discontinued biolo

      Akhil Sood MD, MS AkhilSoodMD

      4 months ago
      LB04: Another approach to CAR-T, CD20+/BCMA bispecific CAR-T in refractory proliferative LN: 🔹100% discontinued biologics & IS at follow-up 🔹Renal response ~78% 🔹CRS mostly Grade 1–2 (~70%); ≥Grade 3 AEs = transient & hematologic @RheumNow #ACR25 https://t.co/oNK4wtLGYV
      Abstract 1563: Ongoing Phase 1/2 trial of Rese-cel CAR-T in systemic sclerosis
      🔹Pt with severe skin involvement show

      Akhil Sood MD, MS AkhilSoodMD

      4 months ago
      Abstract 1563: Ongoing Phase 1/2 trial of Rese-cel CAR-T in systemic sclerosis 🔹Pt with severe skin involvement showed improvement in mRSS (42→34), PFTs & nailfold capillaroscopy at 6 mo 🔹Grade 2 CRS, no ICANS or DLT reported Early but exciting findings @RheumNow #ACR25
      ×